Medical care and payment for diabetes in China: enormous threat and great opportunity.
<h4>Background</h4>The Diabetes Impact Study followed up a large national population-based screening study to estimate the use of and expenditures for medical care caused by diabetes in China and to ascertain the use and cost of essential basic medicines and care.<h4>Methods</h4...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e3b9bfcb43be4ce0a06ead655a88875c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e3b9bfcb43be4ce0a06ead655a88875c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e3b9bfcb43be4ce0a06ead655a88875c2021-11-18T08:13:59ZMedical care and payment for diabetes in China: enormous threat and great opportunity.1932-620310.1371/journal.pone.0039513https://doaj.org/article/e3b9bfcb43be4ce0a06ead655a88875c2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23049727/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>The Diabetes Impact Study followed up a large national population-based screening study to estimate the use of and expenditures for medical care caused by diabetes in China and to ascertain the use and cost of essential basic medicines and care.<h4>Methods</h4>In 2009-10, the study team interviewed 1482 adults with diabetes and 1553 adults with glucose tolerance in the normal range from population-based random samples at 12 sites in China. The response rate was 67%.<h4>Findings</h4>After adjusting for age, sex, and urban/rural location, people with diabetes received 1.93 times more days of inpatient treatment, 2.40 times more outpatient visits, and 3.35 times more medications than people with normal glucose tolerance (all p<0.05). Adjusted expenditures for medical care were 3.38 times higher among people with diabetes than among people with normal glucose tolerance (p<0.01, unadjusted 3.97). Persons who were diagnosed with ≥ 10 years prior to the survey paid 3.75 times as much for medical care as those with ≤ 5 years of diagnosed diabetes. Among persons with diabetes, 45.2% took medication to control blood sugar, 21.1% took an antihypertensive medicine, 22.4% took daily aspirin, and 1.8% took a statin. Over the three months before the interview, 46.1% of persons with diabetes recalled seeing a doctor, 48.9% recalled a blood pressure measurement, and 54.5% recalled a blood sugar test. Over the year preceding the interview, 32.1% recalled a retinal screening and 17.9% recalled a foot examination.<h4>Conclusions</h4>In China, health care use and costs were dramatically higher for people with diabetes than for people with normal glucose tolerance and, in relative terms, much higher than in industrialized countries. Low-cost generic medicines that would reduce diabetes expenditures were not fully used.Wenying YangWenhui ZhaoJianzhong XiaoRui LiPing ZhangKatarzyna Kissimova-SkarbekErin SchneiderWeiping JiaLinong JiXiaohui GuoZhongyan ShanJie LiuHaoming TianLi ChenZhiguang ZhouQiuhe JiJiapu GeGang ChenJonathan BrownPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 9, p e39513 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Wenying Yang Wenhui Zhao Jianzhong Xiao Rui Li Ping Zhang Katarzyna Kissimova-Skarbek Erin Schneider Weiping Jia Linong Ji Xiaohui Guo Zhongyan Shan Jie Liu Haoming Tian Li Chen Zhiguang Zhou Qiuhe Ji Jiapu Ge Gang Chen Jonathan Brown Medical care and payment for diabetes in China: enormous threat and great opportunity. |
| description |
<h4>Background</h4>The Diabetes Impact Study followed up a large national population-based screening study to estimate the use of and expenditures for medical care caused by diabetes in China and to ascertain the use and cost of essential basic medicines and care.<h4>Methods</h4>In 2009-10, the study team interviewed 1482 adults with diabetes and 1553 adults with glucose tolerance in the normal range from population-based random samples at 12 sites in China. The response rate was 67%.<h4>Findings</h4>After adjusting for age, sex, and urban/rural location, people with diabetes received 1.93 times more days of inpatient treatment, 2.40 times more outpatient visits, and 3.35 times more medications than people with normal glucose tolerance (all p<0.05). Adjusted expenditures for medical care were 3.38 times higher among people with diabetes than among people with normal glucose tolerance (p<0.01, unadjusted 3.97). Persons who were diagnosed with ≥ 10 years prior to the survey paid 3.75 times as much for medical care as those with ≤ 5 years of diagnosed diabetes. Among persons with diabetes, 45.2% took medication to control blood sugar, 21.1% took an antihypertensive medicine, 22.4% took daily aspirin, and 1.8% took a statin. Over the three months before the interview, 46.1% of persons with diabetes recalled seeing a doctor, 48.9% recalled a blood pressure measurement, and 54.5% recalled a blood sugar test. Over the year preceding the interview, 32.1% recalled a retinal screening and 17.9% recalled a foot examination.<h4>Conclusions</h4>In China, health care use and costs were dramatically higher for people with diabetes than for people with normal glucose tolerance and, in relative terms, much higher than in industrialized countries. Low-cost generic medicines that would reduce diabetes expenditures were not fully used. |
| format |
article |
| author |
Wenying Yang Wenhui Zhao Jianzhong Xiao Rui Li Ping Zhang Katarzyna Kissimova-Skarbek Erin Schneider Weiping Jia Linong Ji Xiaohui Guo Zhongyan Shan Jie Liu Haoming Tian Li Chen Zhiguang Zhou Qiuhe Ji Jiapu Ge Gang Chen Jonathan Brown |
| author_facet |
Wenying Yang Wenhui Zhao Jianzhong Xiao Rui Li Ping Zhang Katarzyna Kissimova-Skarbek Erin Schneider Weiping Jia Linong Ji Xiaohui Guo Zhongyan Shan Jie Liu Haoming Tian Li Chen Zhiguang Zhou Qiuhe Ji Jiapu Ge Gang Chen Jonathan Brown |
| author_sort |
Wenying Yang |
| title |
Medical care and payment for diabetes in China: enormous threat and great opportunity. |
| title_short |
Medical care and payment for diabetes in China: enormous threat and great opportunity. |
| title_full |
Medical care and payment for diabetes in China: enormous threat and great opportunity. |
| title_fullStr |
Medical care and payment for diabetes in China: enormous threat and great opportunity. |
| title_full_unstemmed |
Medical care and payment for diabetes in China: enormous threat and great opportunity. |
| title_sort |
medical care and payment for diabetes in china: enormous threat and great opportunity. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/e3b9bfcb43be4ce0a06ead655a88875c |
| work_keys_str_mv |
AT wenyingyang medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT wenhuizhao medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT jianzhongxiao medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT ruili medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT pingzhang medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT katarzynakissimovaskarbek medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT erinschneider medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT weipingjia medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT linongji medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT xiaohuiguo medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT zhongyanshan medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT jieliu medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT haomingtian medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT lichen medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT zhiguangzhou medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT qiuheji medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT jiapuge medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT gangchen medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity AT jonathanbrown medicalcareandpaymentfordiabetesinchinaenormousthreatandgreatopportunity |
| _version_ |
1718422078958338048 |